MGNX - MacroGenics EPS misses by $0.08 misses on revenue; provides cash runway guidance

MacroGenics (NASDAQ:MGNX): Q2 GAAP EPS of -$0.66 misses by $0.08. Revenue of $30.8M (+52.0% Y/Y) misses by $1.35M.  Cash, cash equivalents and marketable securities as of June 30, 2021 were $297.3M, compared to $272.5M as of December 31, 2020. MacroGenics anticipates that its cash, cash equivalents and marketable securities as of June 30, 2021, plus consideration received from Zai Lab in July 2021, as well as anticipated and potential collaboration payments, should enable it to fund its operations through 2023, assuming the Company’s programs and collaborations advance as currently contemplated. Press Release

For further details see:

MacroGenics EPS misses by $0.08, misses on revenue; provides cash runway guidance